Chinmanat Lekhavat1, Pinyo Rattanaumpawan2, Isree Juengsamranphong3. 1. Institute of Dermatology, Department of Medical Services, Ministry of Public Health, Bangkok, Thailand. 2. Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 3. Skin Laser and Surgery Department, Dontum Hospital, Nakhon Pathom, Thailand.
Abstract
Introduction: Diphenylcyclopropenone (DPCP) is the medication of choice for the treatment of severe alopecia areata (AA) according to AA treatment guidelines. Precise initiation and application are important factors for successful treatment. However, it is difficult for patients who live far away to visit their doctor weekly. Methods: We conducted a retrospective cohort study to assess the cost, effectiveness, and side effects of DPCP treatment between office-use DPCP (O-DPCP) and home-use DPCP (H-DPCP) in severe AA patients. A cost-effectiveness analysis was performed from the perspective of healthcare providers and patients using real-world data and the national cost statistics for hospital services comparing O-DPCP and H-DPCP in patients with severe AA at 24, 36, and 48 weeks. Results: Two groups of 41 patients treated with O-DPCP and H-DPCP were enrolled. There was no significant difference in the proportion of patients who showed a favorable outcome (≥50% improvement) with minimal side effects between both groups at 24 (O-DPCP 43.9% vs. H-DPCP 26.8%, p = 0.11), 36 (O-DPCP 58.5% vs. H-DPCP 43.9%, p = 0.19), or 48 weeks (O-DPCP 63.4% vs. H-DPCP 56.1%, p = 0.49). The cost of H-DPCP was half of the cost of O-DPCP. Discussion/ Conclusion: H-DPCP is a cost-effective and time-efficient alternative treatment option for severe AA patients.
Introduction: Diphenylcyclopropenone (DPCP) is the medication of choice for the treatment of severe alopecia areata (AA) according to AA treatment guidelines. Precise initiation and application are important factors for successful treatment. However, it is difficult for patients who live far away to visit their doctor weekly. Methods: We conducted a retrospective cohort study to assess the cost, effectiveness, and side effects of DPCP treatment between office-use DPCP (O-DPCP) and home-use DPCP (H-DPCP) in severe AA patients. A cost-effectiveness analysis was performed from the perspective of healthcare providers and patients using real-world data and the national cost statistics for hospital services comparing O-DPCP and H-DPCP in patients with severe AA at 24, 36, and 48 weeks. Results: Two groups of 41 patients treated with O-DPCP and H-DPCP were enrolled. There was no significant difference in the proportion of patients who showed a favorable outcome (≥50% improvement) with minimal side effects between both groups at 24 (O-DPCP 43.9% vs. H-DPCP 26.8%, p = 0.11), 36 (O-DPCP 58.5% vs. H-DPCP 43.9%, p = 0.19), or 48 weeks (O-DPCP 63.4% vs. H-DPCP 56.1%, p = 0.49). The cost of H-DPCP was half of the cost of O-DPCP. Discussion/ Conclusion: H-DPCP is a cost-effective and time-efficient alternative treatment option for severe AA patients.
Authors: Nekma Meah; Dmitri Wall; Katherine York; Bevin Bhoyrul; Laita Bokhari; Daniel Asz Sigall; Wilma F Bergfeld; Regina C Betz; Ulrike Blume-Peytavi; Valerie Callender; Vijaya Chitreddy; Andrea Combalia; George Cotsarelis; Brittany Craiglow; Jeff Donovan; Samantha Eisman; Paul Farrant; Jack Green; Ramon Grimalt; Matthew Harries; Maria Hordinsky; Alan D Irvine; Satoshi Itami; Victoria Jolliffe; Brett King; Won-Soo Lee; Amy McMichael; Andrew Messenger; Paradi Mirmirani; Elise Olsen; Seth J Orlow; Bianca Maria Piraccini; Adriana Rakowska; Pascal Reygagne; Janet L Roberts; Lidia Rudnicka; Jerry Shapiro; Pooja Sharma; Antonella Tosti; Annika Vogt; Martin Wade; Leona Yip; Abraham Zlotogorski; Rodney Sinclair Journal: J Am Acad Dermatol Date: 2020-03-09 Impact factor: 11.527
Authors: Aditya K Gupta; Jessie L Carviel; Kelly A Foley; Neil H Shear; Bianca Maria Piraccini; Vincent Piguet; Antonella Tosti Journal: Skin Appendage Disord Date: 2019-08-29